Xeris Biopharma, Inc.

163 articles about Xeris Biopharma, Inc.

• Xeris Biopharma Reports Second Quarter 2023 Financial Results

  8/8/2023

  Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter and six months ended June 30, 2023 and corporate highlights.

• Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023

  8/1/2023

  Xeris Biopharma Holdings, Inc. today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, August 8, 2023.

• Xeris Ships One Millionth Gvoke® Unit

  7/31/2023

  Xeris Biopharma Holdings, Inc. announced that Xeris has shipped more than one million units of Gvoke® – the company’s ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above.

• Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

  6/21/2023

  Xeris Biopharma Holdings, Inc. today announced that the first participant has been dosed in a multi-center, open label, Phase 2 study of XP-8121 for the treatment of adults with hypothyroidism.

• Xeris Biopharma to Participate at the Jefferies Healthcare Conference

  6/1/2023

  Xeris Biopharma Holdings, Inc. today announced that members of its senior management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8 at 10:30am Eastern Time.

• Xeris Biopharma Reports First Quarter 2023 Financial Results

  5/9/2023

  Xeris Biopharma Holdings, Inc. today announced financial results for the first quarter ended March 31, 2023, and other corporate highlights.

• Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

  5/2/2023

  Xeris Biopharma Holdings, Inc. today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023.

• Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

  4/18/2023

  Xeris Biopharma Holdings, Inc. today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘ METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS .’

• Xeris Biopharma Appoints Ricki Fairley to Board of Directors

  3/29/2023

  Xeris Biopharma Holdings, a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, appointed Ricki Fairley to its Board of Directors, increasing the size of the Board to nine members, on March 27, 2023.

• Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

  3/8/2023

  Xeris Biopharma Holdings, Inc. today announced financial results for the fourth quarter and full-year 2022 and provided 2023 financial guidance.

• Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023

  2/23/2023

  Xeris Biopharma Holdings, Inc. today announced that the Company will release its fourth quarter and full-year 2022 financial results before the open of the U.S. financial markets on Wednesday, March 8, 2023.

• Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023

  2/2/2023

  Xeris Biopharma, Inc. today announced that members of its senior management will hold 1x1 investor meetings and present an overview of the Company at the SVB Securities Global Biopharma Conference 2023, which is taking place in a virtual format.

• Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®

  1/30/2023

  Xeris Biopharma Holdings, Inc. today announced that the Food and Drug Administration (FDA) granted its subsidiary Xeris Pharmaceuticals, Inc., orphan-drug exclusivity (ODE) for Recorlev® (levoketoconazole) for the treatment of adult patients with endogenous Cushing’s syndrome for whom surgery is not an option or has not been curative.

• Xeris Biopharma Updates Its Outlook For 2022

  1/5/2023

  Xeris Biopharma Holdings, Inc. today announced that, in connection with investor meetings the Company is planning to conduct next week in San Francisco, it has updated its outlook for full year 2022 expecting net product revenue to be at the top of its guidance range of $105 million to $110 million and its year-end cash balance to be above the previously announced range of $110 million to $120 million.

• Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/5/2023

  Xeris Biopharma Holdings, Inc. announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 pm Pacific Time.

• Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism

  12/15/2022

  Xeris Biopharma Holdings, Inc. today announced that, based on feedback from a Type C meeting with the Food and Drug Administration (FDA), Xeris will proceed with a Phase II study in patients for its novel formulation of levothyroxine sodium (SC injection) as replacement therapy for hypothyroidism.

• Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab

  11/23/2022

  Xeris Biopharma Holdings, Inc. today announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (Nasdaq: HZNP).

• Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events

  11/9/2022

  Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2022 and other corporate highlights.

• Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022

  11/2/2022

  Xeris Biopharma Holdings, Inc. today announced that the Company will release its third quarter 2022 financial results before the open of the U.S. financial markets on Wednesday, November 9, 2022.

• Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology

  11/1/2022

  Xeris Biopharma Holdings, Inc. today announced that the European Journal of Endocrinology (EJE) published the extended evaluation (EE) results of the SONICS study (NCT01838551) evaluating longer-term effects of levoketoconazole on cortisol levels, biomarkers of Cushing’s syndrome (CS) comorbidities.